On March 3, 2023,
Dawson James
initiated protection of Geovax Labs with
a Purchase suggestion.
Analyst Worth Forecast Suggests 660.03% Upside
As of March 4, 2023,
the typical one-year price target for Geovax Labs is $5.78.
The forecasts vary from a low of $3.03 to a excessive of $8.40.
The typical value goal represents a rise of 660.03% from its newest reported closing value of $0.76.
The projected annual income for Geovax Labs
is $10MM, a rise of 4,038.13%.
The projected annual non-GAAP EPS
is -$0.50.
What are massive shareholders doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 440K shares
representing 1.67% possession of the corporate.
No change within the final quarter.
Renaissance Technologies
holds 410K shares
representing 1.56% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 1,046K shares, representing
a lower
of 154.72%.
The agency
decreased
its portfolio allocation in GOVX by 78.03% over the past quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares
holds 289K shares
representing 1.10% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 108K shares, representing
a rise
of 62.73%.
The agency
elevated
its portfolio allocation in GOVX by 49.49% over the past quarter.
Geode Capital Management
holds 173K shares
representing 0.66% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 146K shares, representing
a rise
of 15.32%.
The agency
decreased
its portfolio allocation in GOVX by 37.16% over the past quarter.
FSMAX – Fidelity Extended Market Index Fund
holds 122K shares
representing 0.47% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 32K shares, representing
a rise
of 74.19%.
The agency
elevated
its portfolio allocation in GOVX by 159.42% over the past quarter.
What’s the Fund Sentiment?
There are 25 funds or institutions reporting positions in Geovax Labs.
That is a lower
of
4
proprietor(s) or 13.79% within the final quarter.
Common portfolio weight of all funds devoted to GOVX is 0.01%,
a rise
of three.45%.
Whole shares owned by establishments decreased
within the final three months by 27.26% to 2,301K shares.
Geovax Labs Background Info
(This description is supplied by the corporate.)
GeoVax Labs, Inc. is a clinical-stage biotechnology firm growing human vaccines towards infectious illnesses and most cancers utilizing a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) primarily based vaccine platform. On this platform, MVA, a big virus able to carrying a number of vaccine antigens, expresses proteins that assemble into VLP immunogens inside (in vivo) the individual receiving the vaccine. The manufacturing of VLPs within the individual being vaccinated mimics virus manufacturing in a pure an infection, stimulating each the humoral and mobile arms of the immune system to acknowledge, stop, and management the goal an infection. The MVA-VLP derived vaccines elicit sturdy immune responses within the host much like a live-attenuated virus, whereas offering the security traits of a replication-defective vector.
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.